Repono Regulatory Approval

Repono Other Announcement

Repono Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending September 30, 2026. This is a routine compliance disclosure.

Repono Capacity Expansion

Repono Ltd received Engineering Scale Plan approval from North Central Railways for its upcoming greenfield rail-fed petroleum oil terminal at Mathura, Uttar Pradesh.

Repono Business Update

Repono Ltd's step-down subsidiary received approval from North Central Railway for a Gati Shakti Cargo Terminal. The approval for the Engineering Scale Plan allows development at Ajhai Station.

From

North Central Railway, Agra Division

Repono Annual General Meeting

Repono Limited held its 09th Annual General Meeting on September 12, 2026. All resolutions were passed with the requisite majority.

Repono Other Announcement

Repono Limited notified the exchange about sending Annual Report web-links to members. It also provided routine reminders regarding KYC and dematerialization requirements for shareholders.

Repono Annual General Meeting

Repono Limited will hold its 9th Annual General Meeting on 12th September 2026 via video conferencing. No dividend has been recommended for the year.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.